Albiglutide (Tanzeum): Why GSK Pulled It and What Replaced It

Albiglutide is the GLP-1 drug almost no one remembers. Albiglutide came and went so quickly that even diabetes specialists sometimes forget it ever shipped.

GSK launched it as Tanzeum in 2014, then quietly walked it off the shelf three years later. The science worked. The sales did not. If you have searched for albiglutide today, you are probably trying to figure out what happened, what to use instead, and how it stacks up against semaglutide and dulaglutide.

What Albiglutide Was

Albiglutide was a long-acting GLP-1 receptor agonist.

GSK built the molecule by fusing two modified GLP-1 peptides to recombinant human albumin. That albumin tail is the trick. Native GLP-1 has a half-life of about two minutes in the bloodstream. Bolted to albumin, albiglutide cleared with a half-life of roughly 5 days, which is what allowed once-weekly dosing instead of the twice-daily injections of older drugs like exenatide.

The FDA approved albiglutide in April 2014 under the brand name Tanzeum. The European Medicines Agency cleared it the same year as Eperzan. Both approvals were for type 2 diabetes in adults, used alongside diet and exercise when other oral medications were not enough. It was never approved as a weight loss drug, and it was never used in type 1 diabetes.

How Albiglutide Worked in the Body

The mechanism was the standard GLP-1 playbook.

Albiglutide binds the GLP-1 receptor on pancreatic beta cells and triggers glucose-dependent insulin release. When blood sugar is high, more insulin comes out. When blood sugar is normal, the effect quiets down, which is why hypoglycemia risk on albiglutide alone is low. It also suppresses glucagon from alpha cells, slows gastric emptying, and acts on appetite centers in the brain to reduce food intake.

The albumin fusion did one more thing besides extending half-life. It made the drug too big to easily cross into the central nervous system, which some researchers think blunted the appetite and weight loss signal compared to smaller GLP-1s like semaglutide. That detail matters because it explains why albiglutide produced only modest weight loss while newer agents drive double-digit drops.

Albiglutide Dosing

Albiglutide dosing was simple by GLP-1 standards.

• Starting dose: 30 mg injected subcutaneously once a week, on the same day each week.
• Titration: If glycemic control was inadequate after several weeks, the dose could be increased to 50 mg once weekly.
• Injection sites: Abdomen, thigh, or upper arm, rotated each week.
• Reconstitution: Albiglutide came as a lyophilized powder in a single-dose pen and required mixing before injection. This was one of the patient-experience problems that hurt the drug commercially.
• Missed dose: If within 3 days, take it. If more than 3 days late, skip it and resume on the next scheduled day.

If you are coming from albiglutide and looking at modern weekly options, the dose conversion is not one to one. Most clinicians switched patients to dulaglutide 0.75 mg or semaglutide 0.25 mg weekly and titrated from there.

Why GSK Pulled Albiglutide From the Market

This is the part most albiglutide articles get wrong.

GSK announced in July 2017 that it would stop selling albiglutide. The decision had nothing to do with new safety signals. Tanzeum's label carried the same boxed warning about thyroid C-cell tumors that every GLP-1 in the class carries. There was no recall, no post-market disaster, and no efficacy reversal.

What killed albiglutide was the market. Three things stacked against it:

1. Weak weight loss. Albiglutide produced only about 1 to 2 kg of weight loss on average. Liraglutide was already beating it, and dulaglutide had launched in late 2014 with better tolerability and a simpler pen.
2. Reconstitution friction. Patients had to mix the powder before injecting. Trulicity and Bydureon BCise came pre-mixed in disposable pens. That mattered more than the FDA filings ever predicted.
3. Smaller HbA1c drops. Albiglutide lowered HbA1c by about 0.6 to 0.9%, while liraglutide and dulaglutide were closer to 1.0 to 1.5% in head-to-head data.

Albiglutide vs Semaglutide vs Dulaglutide

Here is how albiglutide compared with the GLP-1 drugs that pushed albiglutide out of the market.

If you want a deeper breakdown of the GLP-1 class and where modern agents like retatrutide fit, the peptides for weight loss overview covers the full landscape.

Side Effects of Albiglutide

The albiglutide side effect profile was typical for the class.

• GI: Nausea, diarrhea, and vomiting were the most common, but generally milder than with liraglutide or semaglutide because the drug acts less on central appetite pathways.
• Injection site reactions: About 11 to 15% of patients reported redness, itching, or a small bump at the injection site. This was higher than dulaglutide and was another reason for the commercial decline of albiglutide.
• Pancreatitis: Rare but reported, as with all GLP-1 agonists.
• Thyroid C-cell tumors: Boxed warning based on early laboratory findings, contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
• Hypoglycemia: Low risk on its own, higher when combined with insulin or sulfonylureas.

What to Use Instead of Albiglutide

If you found this page because a doctor mentioned albiglutide, or you remember being on Tanzeum years ago, the modern equivalents are easy to map:

• For type 2 diabetes only: Dulaglutide (Trulicity) is the closest match in terms of weekly dosing and tolerability profile.
• For diabetes plus weight loss: Semaglutide (Ozempic for diabetes, Wegovy for obesity) outperforms albiglutide on both glucose and weight by a wide margin.
• For maximum weight loss: Tirzepatide (Mounjaro / Zepbound) and the investigational retatrutide hit GLP-1 plus GIP and glucagon receptors and produce 15 to 24% weight loss in trials.
• For cardiovascular risk reduction: Semaglutide and dulaglutide both have positive cardiovascular outcomes data and have effectively absorbed the niche albiglutide briefly held.

If cost is the issue that originally pushed someone toward albiglutide, the GLP-1 without insurance guide walks through the cheapest legitimate paths to a current GLP-1.

Is Albiglutide Available Anywhere in 2026?

No, albiglutide is not available for new patients.

GSK ceased manufacturing in 2017 and existing inventory was used up by mid-2018. Albiglutide is not available in the US, Europe, or any other major market. Pharmacies will not fill an albiglutide prescription. There is no generic albiglutide, no biosimilar, and no compounded version because the recombinant manufacturing process is proprietary and complex.

If you see "albiglutide for sale" on a research-chemical site, treat it as a red flag. Real recombinant albiglutide does not exist outside the discontinued GSK supply, and counterfeit GLP-1 vials are a documented problem in the gray market.